Table 1.
No. | Year | Ref. | Targeted SNPs | Subject settings | HBe | Result | Comments |
1 | 2010 | Martin et al[20] | rs12979860 | 226 HBV persistence, 384 HBV recovery | ND | Negative | C/C genotype of rs12979860 was not associated with HBV recovery (OR = 0.99) |
2 | 2011 | Li et al[21] | rs12979860, rs12980275, rs8099917 | 203 chronic HBV infection, 203 self-limited HBV infection, 203 individuals negative for all HBV seromarkers (Chinese Han population) | ND | Negative | |
3 | 2011 | Tseng et al[22] | IL28B regions | 115 HBeAg-positive chronic hepatitis B patients | Positive | Negative | |
4 | 2012 | Sonneveld et al[23] | rs12980275, rs12979860 | 205 HBeAg-positive patients who were treated with PEG-IFN (Europeans and Asians) | Positive | Positive | IL28B genotype was significantly associated with HBeAg seroconversion at the end of treatment (P < 0.001, OR = 3.16), during long-term follow up (HR = 2.14), or with HBsAg seroclearance (HR = 3.47) |
5 | 2012 | Wu et al[24] | rs8099917 | 512 HBeAg positive chronic hepatitis B patients (Han Chinese) were treated with pegylated interferon a-2a ± nucleoside analogues | Positive | Positive | The frequency of G allele of rs8099917 was significantly higher in the response group than in the non-response group (8.3% vs 3.9%, P = 0.003, OR = 0.44, 95%CI: 0.25-0.79). The genotype distributions of this SNP also differed significantly between the two groups (P = 0.003) |
6 | 2012 | de Niet et al[25] | rs12979860 | 95 chronic hepatitis B patients who were treated with PEG-IFN and adefovir for 1 yr and who had 15% HBsAg loss (overall) | Positive and negative | Negative | |
7 | 2012 | Peng et al[26] | rs12979860 | 651 HBV persistent infection (387 with liver cirrhosis, 264 without cirrhosis), 226 healthy individuals who recovered from HBV infection | ND | Negative | No association with clearance of HBsAg, HBeAg, HBV DNA level, apparent hepatitis onset and liver cirrhosis (P > 0.05) |
8 | 2013 | Lampertico et al[31] | rs12979860 | 101 HBeAg-negative patients (92% genotype D) with compensated chronic hepatitis B (84% males, 42% with cirrhosis) | Negative | Positive | The rate of serum HBsAg clearance was 29% in CC (major homo) compared to 13% in non-CC (hetero or minor homo) genotype carriers (P = 0.039) |
9 | 2013 | Seto et al[32] | IL28B (rs12979860, rs8099917) | 203 chronic hepatitis B patients achieving spontaneous HBsAg seroclearance with 203 age- and sex-matched chronic hepatitis B patients without HBsAg seroclearance (control) | Negative | Positive | IL28B haplotype block CG was associated with HBsAg seroclearance (OR = 10.5, P = 0.026) |
10 | 2013 | Holmes et al[33] | rs12979860 | 96 patients (88% were Asian, 62% were HBeAg positive and 13% were METAVIR stage F3-4). The majority (84%) of patients carried the CC IL28B genotype (major homo) | Positive and negative | Negative | |
11 | 2013 | Lee et al[34] | rs8099917, rs12979860, rs12980275 | 404 spontaneously recovered patients, 313 chronic hepatitis B patients, 305 liver cirrhosis patients and 417 hepatocellular carcinoma patients | ND | Negative |
Studies are chronologically numbered. HBV: Hepatitis B virus; ND: Not determined or not described; IL: Interleukin; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen; PEG-IFN: Pegylated interferon-α.